Skip to content
10-K

Annual Report

ULTRAGENYX PHARMACEUTICAL INC. RARE

0001193125-26-057329

← back to feed
Filed
Feb 18, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 13, 2026 96.63M sh
Shares Diluted FY 2025 · Dec 31, 2025 98.6M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 90.5M sh
Shares Diluted restated FY 2025 · Dec 31, 2023 73.5M sh
Capex FY 2025 · Dec 31, 2025 $6M
Capex restated FY 2025 · Dec 31, 2024 $7M
Capex restated FY 2025 · Dec 31, 2023 $44M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$466M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$414M
Operating Cash Flow restated FY 2025 · Dec 31, 2023 −$475M
Cash And Equivalents FY 2025 · Dec 31, 2025 $421M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $174M
Cash And Equivalents restated FY 2025 · Dec 31, 2023 $214M
Stockholders Equity FY 2025 · Dec 31, 2025 −$80M
Stockholders Equity restated FY 2025 · Dec 31, 2024 $255M
Stockholders Equity restated FY 2025 · Dec 31, 2023 $275M
Stockholders Equity restated FY 2025 · Dec 31, 2022 $352M
Current Liabilities FY 2025 · Dec 31, 2025 $384M
Current Liabilities restated FY 2025 · Dec 31, 2024 $344M
Total Liabilities FY 2025 · Dec 31, 2025 $1.61B
Total Liabilities restated FY 2025 · Dec 31, 2024 $1.24B
Current Assets FY 2025 · Dec 31, 2025 $951M
Current Assets restated FY 2025 · Dec 31, 2024 $817M
Total Assets FY 2025 · Dec 31, 2025 $1.53B
Total Assets restated FY 2025 · Dec 31, 2024 $1.5B
Eps Diluted FY 2025 · Dec 31, 2025 −$5.83
Eps Diluted FY 2025 · Dec 31, 2024 −$6.29
Eps Diluted FY 2025 · Dec 31, 2023 −$8.25
Eps Basic FY 2025 · Dec 31, 2025 −$5.83
Eps Basic FY 2025 · Dec 31, 2024 −$6.29
Eps Basic FY 2025 · Dec 31, 2023 −$8.25
Sga Expense FY 2025 · Dec 31, 2025 $349M
Sga Expense restated FY 2025 · Dec 31, 2024 $321M
Sga Expense restated FY 2025 · Dec 31, 2023 $310M
Rd Expense FY 2025 · Dec 31, 2025 $750M
Rd Expense restated FY 2025 · Dec 31, 2024 $698M
Rd Expense restated FY 2025 · Dec 31, 2023 $648M
Net Income FY 2025 · Dec 31, 2025 −$575M
Net Income restated FY 2025 · Dec 31, 2024 −$569M
Net Income restated FY 2025 · Dec 31, 2023 −$607M
Operating Income FY 2025 · Dec 31, 2025 −$535M
Operating Income restated FY 2025 · Dec 31, 2024 −$536M
Operating Income restated FY 2025 · Dec 31, 2023 −$569M
Revenue FY 2025 · Dec 31, 2025 $673M
Revenue restated FY 2025 · Dec 31, 2024 $560M
Revenue restated FY 2025 · Dec 31, 2023 $434M